The abstract is read at the publisher; the summary is JClub's.
Cardiomyocyte-derived IL-30 restrains splenic germinal center activation after myocardial infarction in mice, and recombinant IL-30 improves cardiac function.
- Why it matters: After MI, splenic humoral immune responses shape cardiac injury and repair, but the cardiac signals controlling this heart–spleen communication are not well defined.
- What they did: The study used cardiomyocyte-specific IL-30 deficiency and recombinant IL-30 in mice, testing effects on splenic germinal centers, STAT1 phosphorylation, IgG deposition, macrophage TNF-α, apoptosis, and cardiac remodeling; IL-30 effects were blocked by B cell gp130 deletion and absent in splenectomized mice.
- The result: In STEMI patients (n = 75; and 247 longitudinally), lower circulating IL-30 is linked to higher IgG-positive B cell frequencies and independently predicts adverse left ventricular remodeling at 6 months (odds ratio 4.44; 95% CI 2.16–9.80; P<0.001), with discrimination AUC 0.738.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.